WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops
novel anticancer therapeutics using its proprietary antibody-drug
conjugate (ADC) technology, today announced that Gregory D. Perry,
Executive Vice President and Chief Financial Officer, has provided
notice of his intention to resign from the Company to pursue other
interests. His resignation is effective September 13, 2013.
"I sincerely appreciate Greg's service to ImmunoGen over the four years
we have worked together," commented Daniel M. Junius, President and
Chief Executive Officer. "On behalf of the Company, I thank Greg for his
many contributions and wish him well in his future endeavors."
ImmunoGen is initiating a search to hire Mr. Perry's replacement. In the
interim, Mr. Junius will be the Company's acting chief financial officer.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
proprietary ADC technology uses a tumor-targeting engineered antibody to
deliver one of ImmunoGen's highly potent cancer-cell killing agents
specifically to tumor cells. The most advanced compound using
ImmunoGen's TAP technology, Kadcyla®, is marketed in the US
by Genentech, a member of the Roche Group, and undergoing regulatory
review in the European Union and Japan. ImmunoGen has four wholly owned
clinical-stage compounds, with additional compounds in the clinic
through partnerships. More information about ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a trademark of Genentech.
Carol Hausner, 781-895-0600
Director, Investor Relations and Corporate Communications
The Yates Network
Barbara Yates, 781-258-6153
Source: ImmunoGen, Inc.
News Provided by Acquire Media